XML 27 R14.htm IDEA: XBRL DOCUMENT
v3.21.1

EARNINGS PER SHARE | 12 Months Ended
--- | ---
Apr. 03, 2021
Earnings Per Share [Abstract] |
EARNINGS PER SHARE | EARNINGS PER SHARE The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
(In thousands, except per share amounts) | 2021 |  | 2020 |  | 2019
Basic EPS |  |  |  |  |
Net income | $ | 79,469 |  |  | $ | 76,526 |  |  | $ | 55,019 |
Weighted average shares | 50,688 |  |  | 50,692 |  |  | 51,533 |
Basic income per share | $ | 1.57 |  |  | $ | 1.51 |  |  | $ | 1.07 |
Diluted EPS |  |  |  |  |
Net income | $ | 79,469 |  |  | $ | 76,526 |  |  | $ | 55,019 |
Basic weighted average shares | 50,688 |  |  | 50,692 |  |  | 51,533 |
Net effect of common stock equivalents | 604 |  |  | 1,123 |  |  | 1,409 |
Diluted weighted average shares | 51,292 |  |  | 51,815 |  |  | 52,942 |
Diluted income per share | $ | 1.55 |  |  | $ | 1.48 |  |  | $ | 1.04 |
Basic earnings per share is calculated using the Company's weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion value of the convertible senior notes. For fiscal 2021, 2020 and 2019, weighted average shares outstanding, assuming dilution, excludes the impact of 0.5 million, 0.2 million and 0.2 million anti-dilutive shares, respectively. Share Repurchase Plan In May 2019, the Company's Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the two year period ending May 2021. As of April 3, 2021, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $325.0 million. The Company did not make any additional share repurchases under this program which expired in May 2021.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration